Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INCENTA · Entity 5673 | Chief Legal Officer | February 26, 2024 | February 27, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENANTA PHARMACEUTICALS INC
Report date February 26, 2024 · Filed February 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 75,688 |
Reported balance
After 2024-02-26 transaction · row 1
1 source rowRow 1 · 2024-02-26 · Exercise / conversion · Acquired 5,187 · Balance 75,688 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2033-11-22 | Direct | 77,813 |
Reported balance
After 2024-02-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-26 · Exercise / conversion · Disposed 5,187 · Balance 77,813 F2: Such option became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 22, 2023). |
| Common StockSEC Table I · non-derivative | IndirectBy grantor retained annuity trust | 35,926 |
Reported balance
Holding disclosure · report date 2024-02-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 35,926 F1: These shares are held by grantor retained annuity trusts created by the reporting person for the benefit of himself and his two adult children. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held by grantor retained annuity trusts created by the reporting person for the benefit of himself and his two adult children.
F2: Such option became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 22, 2023).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2019 Filed Feb 14, 2019 02:28 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 3,270 | $95.28 | $311,562.33 |
DisclosureSEC source: 0001177648-19-000013 · edgar.xml · nonDerivative · entry 4 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,978 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2018. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $95.00 to $95.76, inclusive. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 02:28 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Tax withholdingCommon Stock | 4,579 | $88.88 | $406,981.52 |
DisclosureSEC source: 0001177648-19-000013 · edgar.xml · nonDerivative · entry 3 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,248 F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 02:28 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-19-000013 · edgar.xml · nonDerivative · entry 2 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,827 F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on January 4, 2017 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2019. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 02:28 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-19-000013 · edgar.xml · nonDerivative · entry 1 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,827 F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on January 4, 2017 that vested as a result of the achievement of a clinical development milestone in calendar 2018 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2019. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 22:21 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $34.70 | $0.00 |
DisclosureSEC source: 0001177648-19-000001 · edgar.xml · derivative · entry 2 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,700 Underlying: Common Stock · 2,000 shares Expires 2024-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 22:21 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 2,000 | $34.70 | $69,400.00 |
DisclosureSEC source: 0001177648-19-000001 · edgar.xml · nonDerivative · entry 1 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 01:35 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $34.70 | $0.00 |
DisclosureSEC source: 0001177648-18-000053 · edgar.xml · derivative · entry 2 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,700 Underlying: Common Stock · 2,000 shares Expires 2024-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 01:35 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 2,000 | $34.70 | $69,400.00 |
DisclosureSEC source: 0001177648-18-000053 · edgar.xml · nonDerivative · entry 1 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2018 Filed Nov 21, 2018 01:35 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $81.20 | $0.00 |
DisclosureSEC source: 0001177648-18-000050 · edgar.xml · derivative · entry 1 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-11-16 F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 16, 2018). Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:20 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $34.70 | $0.00 |
DisclosureSEC source: 0001177648-18-000036 · edgar.xml · derivative · entry 2 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,700 Underlying: Common Stock · 1,500 shares Expires 2024-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:20 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 1,500 | $34.70 | $52,050.00 |
DisclosureSEC source: 0001177648-18-000036 · edgar.xml · nonDerivative · entry 1 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2018 Filed Feb 13, 2018 23:28 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Tax withholdingCommon Stock | 2,065 | $76.85 | $158,684.93 |
DisclosureSEC source: 0001177648-18-000006 · edgar.xml · nonDerivative · entry 3 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,327 F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards. Read SEC document |
| February 12, 2018 Filed Feb 13, 2018 23:28 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 4,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-18-000006 · edgar.xml · nonDerivative · entry 2 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,392 F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 21, 2015 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2018. Read SEC document |
| February 12, 2018 Filed Feb 13, 2018 23:28 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-18-000006 · edgar.xml · nonDerivative · entry 1 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,570 F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 21, 2015 that vested as a result of the achievement of a clinical development milestone in calendar 2018 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2018. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 22:48 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (right to buy) · Derivative | 4,300 | $0.00 Strike: $34.70 | $0.00 |
DisclosureSEC source: 0001177648-18-000001 · edgar.xml · derivative · entry 2 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,200 Underlying: Common Stock · 4,300 shares Expires 2024-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option to purchase a total of 82,500 shares of common stock became exercisable with respect to twenty-five percent (25%) of the shares on May 9, 2015 (the "Anniversary Date"), with the remainder becoming exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years from the Anniversary Date. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 22:48 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 4,300 | $34.70 | $149,210.00 |
DisclosureSEC source: 0001177648-18-000001 · edgar.xml · nonDerivative · entry 1 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,570 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2017 Filed Nov 22, 2017 00:59 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 21,500 | $0.00 Strike: $48.52 | $0.00 |
DisclosureSEC source: 0001177648-17-000042 · edgar.xml · derivative · entry 1 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2027-11-17 F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 17, 2017). Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 22:41 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Tax withholdingCommon Stock | 830 | $29.82 | $24,746.45 |
DisclosureSEC source: 0001177648-17-000005 · edgar.xml · nonDerivative · entry 2 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,270 F2 · shares: Represents the number of shares of common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU award. Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 22:41 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 2,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-17-000005 · edgar.xml · nonDerivative · entry 1 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,100 F1 · shares: Represents shares of common stock issued upon vesting of a performance share unit ("PSU") award granted on February 20, 2015 as a result of the achievement of a clinical development milestone in 2016 and the settlement and issuance of those shares of common stock on Febuary 13, 2017. Read SEC document |
| November 18, 2016 Filed Nov 23, 2016 00:11 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantRestricted Stock Units · Derivative | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-16-000031 · edgar.xml · derivative · entry 2 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units convert into shares of common stock on a one-for-one basis. F3 · derivative.exercise_date: Such restricted stock units will vest as to one half the shares on the third anniversary of the date of award (November 18, 2019) and the remainder on the fourth anniversary of the date of award (November 18, 2020). The restricted stock unit shares that vest will be issued on the first December 15 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements. F3 · derivative.expiration_date: Such restricted stock units will vest as to one half the shares on the third anniversary of the date of award (November 18, 2019) and the remainder on the fourth anniversary of the date of award (November 18, 2020). The restricted stock unit shares that vest will be issued on the first December 15 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements. Read SEC document |
| November 18, 2016 Filed Nov 23, 2016 00:11 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001177648-16-000031 · edgar.xml · derivative · entry 1 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-11-18 F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2016). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.